CompletedNot Applicable

EUS-RFA for Unresectable Pancreatic Cancer

China8 participantsStarted 2020-03-01

Plain-language summary

The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events. The aim of this study was to evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC. Patients with unresectable PDAC who underwent EUS-RFA were included from September 2013 to June 2016. Pre- and post-procedural clinical data was retrospective collected.

Who can participate

Age range20 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age 20 to 80 years old. ② unresectable PDAC based on review of abdominal cross-sectional imaging (CT or MRI) and cytology/ histology results. ③Intolerance to chemotherapy due to side effects or patient's comorbidities. Exclusion Criteria: * Pregnancy or breast-feeding；②ECOG performance status 3 or 4；③Patients with distant metastases or malignant ascites, life expectancy less than 3 months.

What they're measuring

Tumor size

Timeframe: 2 years

Trial details

NCT IDNCT04310111

SponsorFirst People's Hospital of Hangzhou

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-07-25

View on ClinicalTrials.gov More Pancreatic Ductal Adenocarcinoma trials